Opus Genetics (IRD) Net Income Growth (3y) (2013 - 2026)

Opus Genetics (IRD) Net Income Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -3.84%
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 59.17%
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Opus Genetics 263.72 Mn 203.72 Mn - -124.51%

Historic Data

Download Data
DateValue
Mar 31, 2026 -124.51%
Dec 31, 2025 -29.66%
Sep 30, 2025 -56.76%
Jun 30, 2025 -14.62%
Mar 31, 2025 -7.50%
Dec 31, 2024 -77.22%
Sep 30, 2024 -21.17%
Jun 30, 2024 -2.86%
Mar 31, 2024 43.31%
Dec 31, 2023 36.45%
Sep 30, 2023 86.20%
Jun 30, 2023 -45.70%
Mar 31, 2023 -23.32%
Dec 31, 2022 284.41%
Sep 30, 2022 -32.24%
Jun 30, 2022 -25.98%
Mar 31, 2022 -41.19%
Dec 31, 2021 -26.53%
Sep 30, 2021 7.47%
Jun 30, 2021 -22.96%